Li J et al. - In a study to determine the optimal dose of oxaliplatin when combined with a fixed dose of S-1 (40 mg/m2 twice daily on days 1-14) on a 3-week schedule, for pts with advanced and/or metastatic colorectal cancer (mCRC), it was shown that when combined with a fixed dose of S-1 80 mg/m2, oxaliplatin administered at a dose of 130 mg/m2 is tolerable Methods
Pts were required to have histologically proven advanced or mCRC for which they had received no previous chemotherapy
Oxaliplatin was administered intravenously on day 1 every 3 weeks
Pts were divided into 2 groups to receive 2 doses of oxaliplatin - 100 mg/m2 or 130 mg/m2
10 pts were enrolled and were followed up until 50% of the pts progressed
All pts were evaluated for chemotherapy-related toxicity
Results
Maximum tolerated dose was not reached during the first course
1 of 6 pts experienced grade 3 thrombocytopenia at dose level 2 of oxaliplatin; nonhematological toxicity was mild and tolerable
During the full course of treatment, complete response was achieved in 2 of 9 evaluated pts and partial response was achieved in 1 pt
The remaining 6 pts achieved stable disease during first 2 courses of therapy, and 4 pts remained stable at the time of the last follow-up
Median time to progression-free survival was 8.3 months
See all
